Testing a new targeted drug for recurrent glioblastoma
Part of Cancer clinical trials.
This trial tests a new drug called CM93 that targets a specific change (EGFR) in recurrent glioblastoma, a type of brain cancer. The goal is to see if it can slow or stop tumor growth and to find the best dose.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must have a type of brain cancer called glioblastoma that has come back or grown after initial treatment.
- A previous tumor sample must show a specific change called EGFR (a protein that helps cells grow), either as a mutation or extra copies.
- You must have had standard radiation to the brain, with or without chemo, as your first treatment.
- You need to have visible tumor growth on an MRI and be able to provide a tissue sample from a previous surgery for testing.
- You must be 18 or older, be able to care for yourself (Karnofsky score at least 60), and have adequate organ and heart function.
- You cannot have had certain previous treatments, like EGFR inhibitors or certain chemo within a specific time, and must not be pregnant.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial studies different treatment regimens for people with glioblastoma that is either newly diagnosed or has come back. It aims to find which treatment approach works best for controlling the tumor and improving outcomes.
This trial tests an experimental drug called ERAS-801 for people with a type of brain cancer called glioblastoma or gliosarcoma that has a specific genetic change (EGFR amplification or mutation). The study has two groups: one for people whose tumor has come back after treatment, and another for older adults (70+) who are newly diagnosed. The drug targets the EGFR pathway, which may help slow tumor growth.
This trial tests whether testing drugs on your tumor cells in a lab can help find the best treatment for you. It is for people with a specific type of glioblastoma that has not been treated yet.
This study is testing whether special MRI scans and blood tests can help tell the difference between true tumor growth (progression) and a treatment-related reaction called 'pseudoprogression' in people with glioblastoma. The goal is to make treatment decisions more accurate.
This trial tests a combination of two experimental drugs, CTX-009 and CTX-471, for people whose glioblastoma has returned. The goal is to see if these drugs can help control the tumor.
This trial tests a combination of three drugs—trimipramine (an antidepressant), atezolizumab (an immunotherapy), and bevacizumab (a targeted therapy)—in people whose glioblastoma has come back after initial treatment. The goal is to see if this mix can help shrink the tumor or slow its growth.
Hear when a new Glioblastoma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.